Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UMLS:C0011570 (depression)
 172,036 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

Zimelidine, a bicyclic compound, which in animal experiments causes specific inhibition of the uptake of 5-HT, was tried on 15 patients with depression of endogenous type. It produced considerable and highly significant 5-HT uptake inhibition in rat brain slices incubated in blood plasma from the patient under treatment, but no inhibition of NA uptake. Depressive symptoms were effectively relieved or entirely abolished in about two thirds of the patients. Only four patients did not react to the drug, and three of these were probably in need of NA uptake inhibitors, which on other occasions had worked well on their depressions. These three patients showed an extreme degree or retardation. During zimelidine treatment they were not just unaffected but showed signs of excitation, impatience and desperate feelings. These preliminary findings strongly indicate the true existence of depressive cases in need of an NA uptake inhibitor, but completely resistant to a specific 5-HT uptake inhibitor. The final dose of zimelidine was 75 mg b.i.d. This dose, although sufficient in most cases, was obviously somewhat low for a few of our patients. The concentration in blood plasma of zimelidine should probably reach a minimum level of 250 nmol/l and norzimelidine 500 nmol/l, and to achieve this a general dosage of 100 mg b.i.d. is recommended.
 ...
PMID:Preliminary clinical test of zimelidine (H 102/09), a new 5-HT uptake inhibitor. 36 99

The incidence of depression was found to be unrelated to the use of oral contraceptives in this study, which used controlled samples and defined criteria for measuring depression. The survey, conducted in the general practice of one of the authors, was based on the population of a predominantly working class area and used the technique of the Royal College of General Practitioners Oral Contraceptives Study. 335 women currently taking oral contraceptives, mostly combined pills, were matched for age with 2 groups of controls: 172 past takers and 179 non-takers. 3 questionnaires were used: 1) information about the patient's current menstrual history, medical and psychiatric state, 2) a depression rating scale with scores 0-6 indicating virtual absence of depression, 7-12 mild depressive symptoms, and 13+ depressive illness, and 3) The Eysenck Personality Inventory, used to gauge levels of neuroticism. The following results were obtained. 1) the depression scores of non-takers and takers were similar, those of past takers higher; 2) takers and non-takers displayed similar neuroticism scores, while past takers had a smaller percentage of low-neuroticism scores, but higher percentages of scores above 11; and 3) 20% of takers, 22% of non-takers, and 29% of past takers reported diminished libido. An examination of depressive symptoms and certain social and personal factors revealed a positive relationship, which was unaffected by the use of oral contraceptives. Depressive symptoms increased with age in all groups, but particularly in the controls; depression scores in all groups remained unchanged during the premenstrual stage; and depression was more pronounced the higher the number of children and less pronounced in women going out to work. A comparison of neuroticism and depression scores showed a disproportion in controls with high depression and neuroticism scores; neurotic women produce more depressive symptoms and presumably blame them on the pill. 6 tables, 3 figures, and 2 appendices accompany this article.
 ...
PMID:Incidence of depressive symptoms in users of the oral contraceptive. 65 5

A diagnostic dilemma exists when clinicians face patients with atypical recurrent symptoms involving both physical and psychologic elements. Multiple sclerosis (MS) represents such a dilemma. Few authors address themselves to the significance of depressive illness as the initial presentation in MS. Three patients hospitalized solely due to recurrent emotional disorders are described. Depressive symptoms predominated. In each case no precipitant for depression was identified, no previous neurologic diagnosis was entertained by clinician or patient, and multiple prior psychotherapeutic interventions were unsuccessful. The episodic nature of the symptoms and poor response to usually effective treatments created a high index of suspicion for central nervous system disease. A diagnosis of MS was made based on subtle neurologic signs, spinal fluid gamma globulin elevations, and abnormalities in neuropsychological testing. Treatment involved integrated psychiatric and medical measures.
 ...
PMID:Multiple sclerosis--presenting as depressive illness. 83 11

Depressive symptoms assessed by the Beck Depression Inventory were compared in 97 cancer patients, 66 next-of-kin of cancer patients, and 99 physically healthy persons who attempted suicide. Less than a fourth of the cancer patients and a fifth of their next-of-kin but over half of the psychiatric patients were moderately or severely depressed. The two patient groups were indistinguishable in somatic depressive symptoms, both scoring higher then the next-of-kin. The cancer patients and the next-of-kin were indistinguishable in nonsomatic (psychological) depressive symptoms, both scoring lower than the suicide attempters. Younger patients reported more nonsomatic symptoms than older ones. Beck scores and nearness to death were not associated in 57 cancer patients who expired. Vegetative depressive symptoms in cancer patients may reflect advanced disease, but nonsomatic symptoms should be reason for psychiatric consultation.
 ...
PMID:Comparative studies of psychological function in patients with advanced cancer--I. Self-reported depressive symptoms. 89 49

A double-blind clinical trial was carried out to evaluate the efficacy of S-adenosyl-L-methionine (SAMe) in speeding the onset of action of imipramine (IMI). SAMe is a naturally occurring substance that has been shown to possess antidepressant activity with a rapid mode of onset and minimal side effects. Sixty-three outpatients with moderate to severe depression were included in the study. After an initial 1-week placebo period, only 40 patients entered the active treatment phase. During the first 2 weeks of the trial, half of these patients received 200 mg/day of SAMe intramuscularly, while the other half received placebo. Simultaneously, oral IMI was administered to all patients at a fixed dose of 150 mg/day. The onset of clinical response was determined by evaluating patients every second day. By the end of week 2, the parenteral treatment was suppressed and IMI was adjusted according to individual needs. Depressive symptoms decreased earlier in the patients who were receiving the SAMe-IMI combination than in those who were receiving the placebo-IMI combination.
 ...
PMID:Efficacy of S-adenosyl-L-methionine in speeding the onset of action of imipramine. 128 23

Symptoms of depression in the majority of patients immediately following acute myocardial infarctions (AMI) resolve rapidly; they are an adjustment reaction. However, in a group of 552 male patients there were 80 (14.5%) patients with persistent major depressive symptoms during a finite period after AMI. Infarction size was assessed by maximum creatine kinase levels, the QRS-complex and the occurrence of late potentials. These measures did not correlate with the degree of depressed moods in these groups. An arrhythmic event in the early hospitalization phase, a recurrent infarction, dyspnoea, and persistent angina pectoris before the AMI were significantly related to more profound degrees of depression. Patients who reported serious life-events in the last 2 yr before AMI, or who suffered from exhaustion and fatigue in the prehospital phase were subject to significantly higher levels of depression. A prodromal phase prior to hospitalization free of bodily symptoms and the use of denial were related to low levels of depression. The logistic regression model incorporating all univariate significant variables revealed that symptoms of exhaustion and fatigue prior to AMI had the strongest independent correlation with post AMI depression.
 ...
PMID:Factors which provoke post-infarction depression: results from the post-infarction late potential study (PILP). 143 62

Symptoms of depression are frequently reported by people with rheumatoid arthritis (RA). To advance our understanding of how best to assess and treat these symptoms, their meaning must be elucidated. This article explores two possible meanings for the emotional distress of RA patients reported on the Center for Epidemiological Studies Depression (CES-D) scale: (1) Certain CES-D scale items may inflate actual depressive symptom scores. (2) Depressive symptoms are experienced and/or expressed in unique ways in an RA population due to the presence of chronic physical symptoms. In this study of 988 people with RA, it was found that there is some modest inflation of the CES-D scale due to the items of "having difficulty getting going" and "everything was an effort." However, irrespective of the modest inflation of the scale, there is evidence that distress in RA is not a static concept. Distress in this RA population was expressed differently from that of a community population, and within the RA population, distress was expressed differently over time.
 ...
PMID:Characterizing the meaning of psychological distress in rheumatoid arthritis. 145 94

One hundred patients with major depression who had discontinued fluoxetine because of side effects were enrolled in a multicenter, open, 8-week study of sertraline. After a washout period of at least 3 weeks following fluoxetine discontinuation and an additional 1-week, single-blind, placebo washout period, patients began treatment with 50 mg sertraline once daily. Based on the clinician's judgment of patient response, doses were titrated upward if necessary. The maximum daily dose of sertraline was 200 mg. Depressive symptoms and adverse events were assessed weekly. An interim analysis was conducted of the first 93 patients who completed the study. Of 91 evaluable patients, 69 sertraline-treated patients (75.8%) experienced significant improvement in depression. Only 8 of 93 patients (8.6%) discontinued sertraline because of side effects.
 ...
PMID:Are patients who are intolerant to one SSRI intolerant to another? 148 Jul 28

Depressive symptoms have been reported in patients with mild to moderate Alzheimer's disease (AD). Recent evidence suggests that a noradrenergic deficit originating from neuronal degeneration in brainstem nuclei may represent an organic correlate of these disturbances. We examined the neuropathological changes in the locus coeruleus (LC), substantia nigra (SN), basal nucleus of Meynert and cortex of 52 patients (12 male, 40 female, mean age 83.2 +/- 6.4 years) with pathologically verified AD. Fourteen patients (1 male, 13 female) showed signs of depression. The majority of these patients suffered from severe physical disability or sensory impairment and developed persistent delusions, but had less cognitive impairment. Neuronal counts in the LC were significantly lower than in the 38 patients without depression (36.9 +/- 14.0; 51.4 +/- 28.0 neuromelanin-pigmented cells per section per nucleus; F = 3.4, df = 1, 50, P = 0.04). Neuron counts were higher in the basal nucleus of Meynert in depressed AD patients and there were no differences of the neuron numbers in the SN. Depression (main effect; F = 4.5, P = 0.04) contributed significantly to the variance of neuronal counts in the LC, even when covarying for gender, age of onset, cognitive impairment and cortical Alzheimer pathology. The observed disproportionate loss of noradrenergic and cholinergic neurons in the LC and basal nucleus of Meynert may represent an important organic substrate of depression in AD.
 ...
PMID:Clinical and neuropathological correlates of depression in Alzheimer's disease. 148 85

This study examines the prevalence of negative symptoms, and assesses the convergence of negative and depressive symptoms in 60 chronically ill schizophrenic outpatients. Negative symptoms were assessed with the Scale for the Assessment of Negative Symptoms and the negative symptom cluster of the Brief Psychiatric Rating Scale (BPRS). Depressive symptoms were assessed with the depression subscale of the Brief Symptom Inventory and the depressive symptom cluster of the BPRS. A majority of patients in this group of relatively stable, schizophrenic outpatients demonstrated mild to moderate degrees of both negative and depressive symptoms. Correlations were not significant between negative symptom and depressive symptom measures, which suggests that the symptom constructs are relatively independent. Comparisons between a subgroup with prominent negative symptoms (N = 18) and a subgroup with minimal negative symptoms (N = 32) also revealed no significant group differences in variables that characterize clinical course (i.e., age of onset and frequency and duration of hospitalization) or in the severity of depressive symptoms. This lack of any significant differences on the clinical course variables may be partially explained by the heterogeneity of negative symptoms. The constellation of negative symptoms may differ not only in etiology but also in their temporal relationships to other aspects of the patient's clinical course. Longitudinal studies will be needed to track the long-term outcome of negative and depressive symptoms.
 ...
PMID:Negative symptomatology in schizophrenic outpatients. 150 Sep 33


1 2 3 4 5 6 7 8 9 10 Next >>